Talking it out: brief sessions may ease lung cancer Survivors' transition
NCT ID NCT05087251
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a few counseling sessions can improve quality of life for adults who have just finished lung cancer treatment with the goal of cure. One group gets five sessions focused on coping skills and social support; the other gets one session with referrals. Researchers will track changes in quality of life, fear of cancer returning, and symptoms over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- psychoeducational counseling sessions
- What this could lead to
- If it works, this could provide a simple, non-drug way to help lung cancer survivors feel better emotionally and socially after treatment ends.
- What could go wrong
- This is a small, early-stage study with only 100 people, so results may not apply to everyone. The intervention is brief and may not produce lasting improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2021
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 21 or older * Able to read and respond in English * Diagnosis of non-small cell lung cancer or small cell lung cancer * Documented curative treatment plan including systemic therapy +/- radiation and +/- surgery * Completed cancer treatment within past 3 weeks * If final treatment is systemic therapy +/- radiation: within 3 weeks after cancer care team determination that treatment is complete * If final treatment is surgery: within 3 weeks after hospital discharge following surgery Exclusion Criteria: * Comorbid health condition that would interfere with study participation * Current participation in cognitive behavioral therapy treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- New PET tracer aims to light up hidden cancer targets
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Breath-Tracking sensor aims to sharpen lung cancer scans